Boehringer Ingelheim Extends Scope of Collaboration with Evotec into Screening Services
New agreements signed with Boehringer Ingelheim Germany and Canada
Advertisement
Evotec AG announced that Boehringer Ingelheim (Boehringer) has extended the scope of its collaboration with Evotec. In addition to the substantial discovery programme to jointly identify and develop therapeutics acting on G-Protein Coupled Receptors (GPCRs) Boehringer research sites in Biberach (Germany) and Laval (Canada) will now collaborate with Evotec under a fee-for-service agreement.
For selected Boehringer target proteins, Evotec will apply its skills in biochemical and cellular assay development as well as in ultra-high-throughput screening (uHTS) using its proprietary FCS+plus detection platform to rapidly and accurately identify promising hit molecules from Boehringer's and Evotec's compound libraries. Active compounds will be further progressed by Boehringer to develop novel treatments for different diseases.